GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » enVVeno Medical Corp (NAS:NVNO) » Definitions » ROC (Joel Greenblatt) %

enVVeno Medical (enVVeno Medical) ROC (Joel Greenblatt) % : -1,362.55% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is enVVeno Medical ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. enVVeno Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1,362.55%.

The historical rank and industry rank for enVVeno Medical's ROC (Joel Greenblatt) % or its related term are showing as below:

NVNO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -24728   Med: -1302.61   Max: -866.29
Current: -1322.58

During the past 9 years, enVVeno Medical's highest ROC (Joel Greenblatt) % was -866.29%. The lowest was -24728.00%. And the median was -1302.61%.

NVNO's ROC (Joel Greenblatt) % is ranked worse than
92.61% of 852 companies
in the Medical Devices & Instruments industry
Industry Median: -0.455 vs NVNO: -1322.58

enVVeno Medical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 34.90% per year.


enVVeno Medical ROC (Joel Greenblatt) % Historical Data

The historical data trend for enVVeno Medical's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

enVVeno Medical ROC (Joel Greenblatt) % Chart

enVVeno Medical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -1,184.95 -866.29 -953.33 -1,039.05 -1,302.61

enVVeno Medical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,277.33 -1,359.40 -1,138.69 -1,438.26 -1,362.55

Competitive Comparison of enVVeno Medical's ROC (Joel Greenblatt) %

For the Medical Devices subindustry, enVVeno Medical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


enVVeno Medical's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, enVVeno Medical's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where enVVeno Medical's ROC (Joel Greenblatt) % falls into.



enVVeno Medical ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.511) - (0.427 + 0 + 0.606)
=-0.522

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.306) - (0.747 + 0 + 0.396)
=-0.837

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of enVVeno Medical for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-22.012/( ( (1.681 + max(-0.522, 0)) + (1.55 + max(-0.837, 0)) )/ 2 )
=-22.012/( ( 1.681 + 1.55 )/ 2 )
=-22.012/1.6155
=-1,362.55 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


enVVeno Medical  (NAS:NVNO) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


enVVeno Medical ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of enVVeno Medical's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


enVVeno Medical (enVVeno Medical) Business Description

Traded in Other Exchanges
Address
70 Doppler, Irvine, CA, USA, 92618
enVVeno Medical Corp is a medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
Executives
Hamed Alavi officer: Chief Technology Officer ENVVENO MEDICAL CORPORATION, 70 DOPPLER, IRVINE CA 92618
Francis Duhay director HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Sanjay Shrivastava director HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert Andrew Berman director, officer: CEO C/O ITUS CORPORATION, 12100 WILSHIRE BOULEVARD, SUITE 1275, LOS ANGELES CA 90025
Matthew Jenusaitis director 2 GOODYEAR, IRVINE CA 92618
Robert Gray director 70 DOPPLER, IRVINE CA 92618
Marc H. Glickman officer: See Remarks 70 DOPPLER, IRVINE CA 92618
Biodyne Holding, S.a. 10 percent owner 13 RUE DE LA GARE, MORGES V8 1110
Craig Glynn officer: Chief Financial Officer 70 DOPPLER, IRVINE CA 92618
Marcus W. Robins director C/O HANCOCK JAFFE LABORATORIES, INC., 70 DOPPLER, IRVINE CA 92618
Robert A Rankin officer: Chief Financial Officer 9200 SUNSET BLVD., SUITE 425, WEST HOLLYWOOD CA 90069
Browston Trading Ltd 10 percent owner P.O. BOX 20533, NICOSIA G4 1660
Robert W. Doyle director 70 DOPPLER, IRVINE CA 92618
Robert A. Anderson director 70 DOPPLER, IRVINE CA 92618
Susan Montoya officer: See Remarks 70 DOPPLER, IRVINE CA 92618